Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T
(2019)
Nature 569: 131-135
MeSH Terms: Animals, Antibodies, Monoclonal, Carcinogenesis, Carcinoma, Pancreatic Ductal, Cell Differentiation, Cell Line, Tumor, Disease Progression, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition, Female, Humans, Leukemia Inhibitory Factor, Male, Mass Spectrometry, Mice, Pancreatic Neoplasms, Paracrine Communication, Receptors, OSM-LIF, Tumor MicroenvironmentAdded March 13, 2021